Capital World Investors Sells 139,297 Shares of AbbVie Inc. $ABBV

Capital World Investors lowered its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.2% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 6,335,283 shares of the company’s stock after selling 139,297 shares during the period. Capital World Investors owned approximately 0.36% of AbbVie worth $1,466,782,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of AbbVie in the second quarter worth approximately $4,288,200,000. Laurel Wealth Advisors LLC grew its stake in shares of AbbVie by 18,384.4% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the period. Vanguard Group Inc. grew its position in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of AbbVie by 169.3% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after purchasing an additional 2,969,202 shares in the last quarter. Finally, Raymond James Financial Inc. raised its stake in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the period. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent analyst reports. Barclays initiated coverage on shares of AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Morgan Stanley upped their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday. Finally, Citigroup dropped their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $226.68 on Wednesday. The company has a market cap of $400.81 billion, a P/E ratio of 96.05, a P/E/G ratio of 0.79 and a beta of 0.34. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm’s fifty day moving average is $224.60 and its two-hundred day moving average is $224.45.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported positive topline results from the Phase 1 multiple ascending dose study of ABBV-295 (long‑acting amylin analog) showing roughly 7.8–9.8% mean weight loss at ~12 weeks and a favorable tolerability profile — supports further development in chronic weight management and expands non‑incretin obesity options. AbbVie reports topline data from Phase I ABBV-295 trial
• Positive Sentiment: AbbVie announced positive Phase 3 AFFIRM results for SKYRIZI (risankizumab) subcutaneous induction in Crohn’s disease — a potential label/indication expansion that could extend revenue runway for an existing franchise. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study
• Positive Sentiment: Industry coverage highlights ABBV‑295 and early obesity program data (up to ~10% weight loss) as a differentiator vs. incretin therapies — this boosts perception of AbbVie’s cardiometabolic pipeline optionality. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study
• Positive Sentiment: J.P. Morgan reiterated its Buy stance on ABBV, an institutional vote of confidence that can support demand for the shares. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Citi’s Geoff Meacham maintained a Hold and $230 price target, signaling caution despite pipeline promise and limiting upside from analyst revisions. Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
• Neutral Sentiment: ResearchAndMarkets published an Elahere (mirvetuximab) market report outlining growth drivers in ovarian cancer — useful long‑term market context but not an immediate mover for ABBV shares. Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026
• Neutral Sentiment: AbbVie’s presentation/transcript at the Leerink Global Healthcare Conference provides management insight on growth drivers and pipeline prioritization — useful for modeling but not an immediate catalyst. AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: ICER (cost‑effectiveness body) will review AbbVie’s Parkinson’s drug — an adverse assessment could limit pricing power/reimbursement and pressure long‑term revenue assumptions. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Governance/headline risks: CEO Robert Michael received a sizable pay increase to $32.5M in year two, and an AbbVie SVP sold ~$1.22M in shares — both items can weigh on sentiment among governance‑focused investors. AbbVie’s Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock

Insider Buying and Selling

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is currently owned by insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.